Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2025 16:15 ET | Source: Surrozen, Inc.

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2025 16:15 ET | Source: Surrozen, Inc.

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen to Present at H.C. Wainwright 27th Annual Global Investment Conference
August 28, 2025 16:15 ET | Source: Surrozen, Inc.

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen management will present at the Cantor Global Healthcare Conference 2025 on Thursday, September 4, 2025
August 08, 2025 16:05 ET | Source: Surrozen, Inc.

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
August 06, 2025 16:30 ET | Source: Surrozen, Inc.

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Wednesday, August 13, 2025
May 14, 2025 08:30 ET | Source: Surrozen, Inc.

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
May 09, 2025 16:05 ET | Source: Surrozen, Inc.

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Surrozen Reports First Quarter 2025 Financial Results and Business Update
March 31, 2025 16:05 ET | Source: Surrozen, Inc.

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
March 24, 2025 09:00 ET | Source: Surrozen, Inc.

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

SRZN Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Disease
November 06, 2024 16:30 ET | Source: Surrozen, Inc.

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen to Present at Upcoming Healthcare Investor Conferences in November 2024